Phase I Dose Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

CONCLUSIONS: The linsitinib/erlotinib combination was tolerable with preliminary evidence of activity, including durable responses in cases unlikely to respond to erlotinib monotherapy.
PMID: 26831715 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 1, 2016 Category: Cancer & Oncology Authors: Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens A, Gadgeel SM Tags: Clin Cancer Res Source Type: research